Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sotrastaurin (AEB071)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

PKC inhibitor

Related drugs:

GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	mirdametinib + AEB071 Sensitive: D – Preclinical mirdametinib + AEB071 Sensitive : D	mirdametinib + AEB071 Sensitive: D – Preclinical mirdametinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	mirdametinib + AEB071 Sensitive: D – Preclinical mirdametinib + AEB071 Sensitive : D	mirdametinib + AEB071 Sensitive: D – Preclinical mirdametinib + AEB071 Sensitive : D
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D	AEB071 Sensitive: D – Preclinical AEB071 Sensitive : D